More recently, hepatocyte-specific targeting of TLR4 ameliorated hepatic steatosis and improved insulin resistance but did not affect weight, while macrophage-specific targeting of TLR4 did not protect mice from DIO, insulin resistance or hepatic steatosis95. Here, TLR4 is linked to fatty liver disease.